Loading
Labs already get tested on whether they score biomarkers correctly, but the results are private. Publishing them would let hospitals and patients avoid labs that get it wrong.
External quality assessment schemes (NordiQC, UK NEQAS, CAP) show that a meaningful fraction of laboratories fail proficiency runs for HER2, PD-L1, ALK and other predictive markers. Results are confidential. Mandatory participation for any laboratory running companion diagnostics and public reporting of pass rates by laboratory, as is done for hospital infection rates, would create accountability and steer referrals.
Shares Companion diagnostics, Biomarkers are not validated or standardised.
Shares Companion diagnostics, Fragmented care and guideline gaps, Biomarkers are not validated or standardised.
Shares Monitor biomarker positivity rates across labs in real time to catch assay drift, Biomarkers are not validated or standardised.
Shares Companion diagnostics, Fragmented care and guideline gaps, Biomarkers are not validated or standardised.
Shares Companion diagnostics, Histopathology & immunohistochemistry.
Shares Record how long tissue waited before fixation in every pathology report, Monitor biomarker positivity rates across labs in real time to catch assay drift, Biomarkers are not validated or standardised.
Shares Companion diagnostics, Biomarkers are not validated or standardised.
Shares Companion diagnostics, Biomarkers are not validated or standardised.